AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04622891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: azithromycin group
Study NCT06795698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: enoxaparin 1mg/kg of ideal body weight subcutaneous every 24 hours in patients with eGFR \<30ml/min/1.73m2
Study NCT06795698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enoxaparin
Description: enoxaparin 1mg/kg of ideal body weight subcutaneous every 24 hours in patients with eGFR \<30ml/min/1.73m2
Study NCT04622891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: control group
Study NCT01986231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg. Glucagon will be reconstituted immediately prior to administration and each dose will be administered subcutaneously via syringe/needle. The first glucagon dose is at hour 17, second at hour 22, third at hour 24, fourth at hour 27, fifth at hour 29, sixth at hour 31, seventh at hour 33, eighth at hour 35.
Study NCT02479087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma-derived FVIII/VWF concentrate
Description: The investigational treatment is with lyophilized plasma-derived Factor VIII. The product belongs to the factor VIII concentrates class, containing also VW Factor in an average ratio VW/VIII of > 1: 4.5.~The product is as a powder and a solvent solution for continuous infusion of Factor VIII. The specific activity of Factor VIII is of approximately 80 IU/mg protein.~The number of units of FVIII administered is expressed in International Units (IU), which are consistent with current WHO standards for products containing Factor VIII. The activity of Factor VIII in plasma is expressed either as a percentage (compared to normal human plasma) or in International Units (compared to the international standard for FVIII in plasma).
Study NCT01965769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No gastric residual evaluation
Description: Infants will not receive routine gastric residual evaluation prior to feeding.
Study NCT02719964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Attention Program (UCR Games)
Description: This program is an individual-directed computerized cognitive rehabilitation program based on perceptual learning approaches to enhance visual attention. Training incorporates a diverse set of stimuli, optimized stimulus presentation, multisensory facilitation, and consistently reinforcing training stimuli. This will be completed in a group setting with an instructor available to facilitate questions.
Study NCT02719964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech Pathologist-Directed Therapy
Description: This is a speech pathologist-directed arm and will provide a traditional clinician-directed individualized cognitive rehabilitation program. Cognitive treatment is a systematic, functionally oriented program of therapeutic activities that focuses on strengthening previously learned patterns of behavior, establishing new patterns through use of internal and external compensatory cognitive strategies, and enabling the individual to adapt to the changes in his or her revised approaches to cognitive functioning. Increased performance success is reinforced through repetition, errorless learning, and gradually increasing task stimuli and complexity in a structured systematic approach.
Study NCT02719964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Cognitive Rehabilitation Games (Lumosity)
Description: Lumosity is a commercially available computerized program purported to enhance cognitive functioning through a variety of computerized programs that utilize various cognitive abilities.
Study NCT04206254 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp96
Description: heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells.
Study NCT03811769 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best Medical Therapy
Description: The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies.
Study NCT03811769 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mechanical Thrombectomy
Description: MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus BMT arm start of treatment is defined as the date and time of groin puncture (arterial access).
Study NCT03886740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reducing symptoms of Eustachian tube dysfunction
Description: One of two methods of reducing Eustachian Tube dysfunction will be performed and the Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) scores will be compared
Study NCT02489253 — intervention group
Intervention type: OTHER
Intervention: CT coronary angiogram and carotid ultrasound
Description: Scans in addition to routine clinical care
Study NCT00519688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100 mg, BID
Study NCT02720380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buteyko
Description: Intervention will be held twice a week during 3 weeks.
Study NCT02720380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asthma education
Description: Educational interventions in relation to asthma will be given to children assigned to the control group.
Study NCT00519688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur/Uracil
Description: 125 mg/m2, based on tegafur, BID
Study NCT02549586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplant
Description: Step 1: Participants will receive intravenous chemotherapy and cytokine-based treatment for mobilization of hematopoietic stem cells (HSC) into the circulation, followed by collection using peripheral vein leukopheresis. The HSC graft product will undergo ex vivo purification with CD34 selection using Miltenyil CliniMACS and cryopreserved.~Step 2: Intravenous busulphan, cyclophosphamide and anti-thymocyte globulin will be administered to participants to achieve immune ablation prior to the infusion of the participants' own thawed HSC graft product (HSC transplant). Routine supportive measures will be employed during the recovery from the chemotherapy and HSCT. Participants' immune suppression will be stopped at the time of immunoablative therapy and will be switched to everolimus which will be discontinued at 6 months post HSCT.
Study NCT03735628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib: lyophilisate for reconstitution and further dilution for infusion
Study NCT04328961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy
Study NCT04328961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ascorbic Acid
Description: Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.
Study NCT02244814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate/Conventional
Description: Lower-carbohydrate/conventional diet (usual care)
Study NCT02244814 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Carbohydrate/Conventional
Description: Lower-carbohydrate/conventional diet (usual care)
Study NCT02244814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choosing Healthy Options in Carbohydrate Energy
Description: Choosing Healthy Options in Carbohydrate Energy
Study NCT02244814 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Choosing Healthy Options in Carbohydrate Energy
Description: Choosing Healthy Options in Carbohydrate Energy
Study NCT03735628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab: concentrate for solution for infusion
Study NCT04530435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEP flute
Description: Participants are advised to use a PEP flute at least three times daily at an appropriate resistance. Ideally, each session consists of 15 breaths (for approximately 1 minute) repeated twice at an upright position.
Study NCT03735199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCL-TCP scaffold
Description: During the surgery, the scaffold will be shaped by cutting and shaving with a scalpel so as to fit the extraction socket snugly at the crestal half to two-thirds aspect. A collagen membrane will be placed over the scaffold at the crestal aspect of the socket. The periosteum of the buccal flap will then be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
Study NCT03735199 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Geistlich Bio-Gide collagen membrane
Description: A collagen membrane will be placed over the crestal aspect of the socket and the periosteum of the buccal flap will be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
Study NCT03735199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geistlich Bio-Gide collagen membrane
Description: A collagen membrane will be placed over the crestal aspect of the socket and the periosteum of the buccal flap will be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
Study NCT01771692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extraction
Description: Extraction of teeth in the lower arch as part of the orthodontic treatment plan
Study NCT01771692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non extraction
Description: Non extraction in the lower arch as part of the orthodontic treatment plan
Study NCT00501592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INT-747
Description: 25 mg by mouth once daily, 50 mg by mouth once daily
Study NCT00501592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03808493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438 OD
Description: TAK-438 OD tablet
Study NCT03808493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablet
Study NCT03741712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3680
Description: Tablet. Specifications of 80mg
Study NCT03741712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554
Description: Tablet. Specifications of 50mg and 200mg
Study NCT01903135 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood test analysis in the clinical labs
Description: for specific measurement of plasmatic bicarbonate
Study NCT01975545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluor varnish
Description: Dental varnish will be applied to one anterior superior teeth in a random side.
Study NCT01975545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluor varnish with nanoparticles
Description: Dental varnish with silver nanoparticles will be applied to one anterior superior teeth in a random side.
Study NCT02743559 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mechanical Stimulation using whole body vibration
Description: All participants will undergo whole body vibration (WBV) by standing on the LivMD WBV platform on 5 consecutive mornings
Study NCT06176443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One anastomosis gastric bypass with combined fundoplication
Description: FundoRingOAGB
Study NCT02321917 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MECC system with rheoparin coating
Description: MECC system for extracorporeal circulation equipped with rheoparin coating.
Study NCT01903135 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pneumologist consult to establish the diagnosis of OHS
Description: complete respiratory check-up: Arterial blood gases analysis, spirometry, anthropometry, polygraphy or polysomnography.~Medical history, previous treatments.
Study NCT00127452 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: margarine spread
Description: Daily use of margarine spread (approximately 20 grams) during 40 months
Study NCT00127452 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: margarine spread
Description: Daily use of margarine spread (approximately 20 grams) during 40 months
Study NCT04362488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative evaluation
Description: Preoperative evaluation using differents clinical evaluation tests, questionnaires, and instrument:~* Delos system (computerized oscillating platform)~* Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~* modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)
Study NCT04362488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative evaluation
Description: Postoperative evaluation at 4 months of follow up after surgery using differents clinical evaluation tests, questionnaires, and instrument:~* Delos system (computerized oscillating platform)~* Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~* modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)
Study NCT03682289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Given orally
Study NCT02743559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Stimulation using whole body vibration
Description: All participants will undergo whole body vibration (WBV) by standing on the LivMD WBV platform on 5 consecutive mornings
Study NCT03682289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given orally
Study NCT03682289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given intravenously (IV)
Study NCT00227344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF ablation
Description: Catheter ablation with NAVISTAR® THERMOCOOL® Catheter in conjunction with CARTO™ EP Navigation System
Study NCT00227344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drugs
Description: Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study
Study NCT02377752 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV
Study NCT02377752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered IV
Study NCT03625947 — intervention group
Intervention type: OTHER
Intervention: Argon Plasma Coagulation
Description: Patients will be treated with Argon Plasma Coagulation. Argon plasma coagulation (APC) is a form of non contact electrocoagulation. APC utilizes electrically conductive argon plasma as a medium to deliver high-frequency current via a flexible probe. The argon plasma flow transfers electricity between the probe and the target tissue. Tracheobronchial access is obtained by passing the probe through the working channel of the bronchoscope. On arrival to the tissue, the application of energy causes uniform zones of desiccation, coagulation and devitalization in the areas receiving treatment, thus inducing hemostasis.
Study NCT01558492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC = 5 intravenously (IV) on day 1 of a 28 day cycle
Study NCT01558492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 intravenously (IV) weekly on days 1, 8, and 15 of a 28 day cycle
Study NCT04384484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous Infusion
Study NCT04384484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous Infusion
Study NCT04384484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Intravenous Infusion
Study NCT04384484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Intravenous Infusion
Study NCT04384484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Intravenous Infusion
Study NCT03323463 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: F-FMISO PET/CT Scan
Description: All subjects on Cohort A and the first 100 subjects accrued to Cohort B will undergo a pre-treatment F-FMISO scan PET/CT scan pretreatment. For both Cohort A and Cohort B, FMISO scan will be repeated between the 5th-10th RT day if pre-treatment scan is hypoxic. If the repeat 18F-FMISOscan PET/CT demonstrates hypoxia, the subject will receive 70Gy concurrent with 2 cycles of chemotherapy. All subjects accrued onto Cohort B after 100 accruals will undergo only one 18F-FMISO scan done 5-10 treatment days after start of radiation therapy.
Study NCT01104493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Frozen FluMist®
Description: Single dose of monovalent vaccine (240 subjects) by intranasal spray on Study Day 1.
Study NCT01104493 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo (60 subjects) by intranasal spray on Study Day 1
Study NCT01224431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffered Lidocaine J-tip
Description: All patients were administered the J-tip and randomized to either treatment with 1% lidocaine or an equivalent amount of sterile normal saline prior to lumbar puncture. Vital signs were recorded during the procedure. Facial expressions were video recorded
Study NCT01224431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buffered Lidocaine J-tip
Description: All patients were administered the J-tip and randomized to either treatment with 1% lidocaine or an equivalent amount of sterile normal saline prior to lumbar puncture. Vital signs were recorded during the procedure. Facial expressions were video recorded
Study NCT00756860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 223
Description: 2 g AMG 223 (4 x 500 mg capsules ) TID on Days 1 through 7
Study NCT00756860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renagel® (sevelamer hydrochloride)
Description: 2g Renagel® (2 x 800 mg capsules + 1 x 400 mg capsule) TID on Days 1 through 7
Study NCT01514929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHN-490 Injection
Description: 20mg/kg IV 30 minute infusion given once
Study NCT01514929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHN-490 Injection
Description: 15mg/kg IV 30 minute infusion given once
Study NCT01514929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400mg oral pill given once
Study NCT01514929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral pill given once
Study NCT01342796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59C.1-adjuvanted subunit influenza vaccine
Description: 2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
Study NCT01342796 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sub unit, Inactivated, Influenza vaccine
Description: 2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
Study NCT03902574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole ODT 2mg with water
Description: Brexpiprazole ODT 2mg is administered with water.
Study NCT03902574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole ODT 2mg without water
Description: Brexpiprazole ODT 2mg is administered without water.
Study NCT03902574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole conventional tablet 2mg
Description: Brexpiprazole conventional tablet 2mg is administered with water.
Study NCT06176443 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One anastomosis gastric bypass without combined fundoplication
Description: OAGB
Study NCT03323463 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 30 Gy over 3 weeks
Description: Treatment will be delivered as one fraction per day on a standard 5 day per week schedule (excluding weekends and holidays), total of 30 Gy over 3 weeks at 2 Gy per fraction each day. The gross nodes, the primary/postoperative bed if applicable, all subclinical areas at risk for disease will receive the same dose at 30Gy.
Study NCT03323463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cycle 1 (week 1): At the start of week 1 of IMRT, subjects will receive cisplatin 100 mg/m2 intravenously. They may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 1 and 2, or as a single dose, typically on day 1.